400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Protein Tyrosine Kinase/RTK / Src / Saracatinib/塞卡替尼
CAS No.: 379231-04-6
Synonyms: AZD 0530;塞卡替尼
Saracatinib is Src inhibitor with IC50 of 2.7 nM.
生物活性
靶点 | Src IC50:2.7nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01144481 | - | - | Completed | - | Canada, Ontario ... more >> University Health Network Toronto, Ontario, Canada, M5G 2C4 Collapse << |
NCT00265876 | Pancreatic Cancer | Phase 1 Phase 2 | Completed | - | Canada, British Columbia ... more >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Algoma District Cancer Program Sault Ste. Marie, Ontario, Canada, P6B 0A8 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT01000896 | Cancer Non Sm... more >>all Cell Lung Cancer Epithelial Ovarian Cancer Collapse << | Phase 1 | Withdrawn(AstraZeneca has disc... more >>ontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..) Collapse << | March 2011 | Japan ... more >> Research Site Matsuyama, Ehime, Japan Research Site Fukuoka, Japan Collapse << |
实验方案
技术信息
CAS号 | 379231-04-6 | 储存条件 |
|
|||||||||||||
分子式 | C27H32ClN5O5 | 运输 | 蓝冰 | |||||||||||||
分子量 | 542.03 | 别名 | AZD 0530;塞卡替尼 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
697 | - | Growth Inhibition Assay | - | IC50=13.2701 μM | SANGER |
A253 | - | Growth Inhibition Assay | - | IC50=35.7429 μM | SANGER |
A388 | - | Growth Inhibition Assay | - | IC50=5.63667 μM | SANGER |
A704 | - | Growth Inhibition Assay | - | IC50=0.8921 μM | SANGER |
ALL-PO | - | Growth Inhibition Assay | - | IC50=27.081 μM | SANGER |
BB30-HNC | - | Growth Inhibition Assay | - | IC50=0.86203 μM | SANGER |
BB49-HNC | - | Growth Inhibition Assay | - | IC50=6.73206 μM | SANGER |
BB65-RCC | - | Growth Inhibition Assay | - | IC50=7.94904 μM | SANGER |
BE-13 | - | Growth Inhibition Assay | - | IC50=14.3915 μM | SANGER |
Becker | - | Growth Inhibition Assay | - | IC50=4.66416 μM | SANGER |
BL-70 | - | Growth Inhibition Assay | - | IC50=2.47422 μM | SANGER |
BOKU | - | Growth Inhibition Assay | - | IC50=9.96466 μM | SANGER |
BV-173 | - | Growth Inhibition Assay | - | IC50=0.65249 μM | SANGER |
C2BBe1 | - | Growth Inhibition Assay | - | IC50=1.20507 μM | SANGER |
CGTH-W-1 | - | Growth Inhibition Assay | - | IC50=6.02075 μM | SANGER |
COLO-320-HSR | - | Growth Inhibition Assay | - | IC50=28.0373 μM | SANGER |
CP67-MEL | - | Growth Inhibition Assay | - | IC50=45.6241 μM | SANGER |
CTB-1 | - | Growth Inhibition Assay | - | IC50=13.5948 μM | SANGER |
CTV-1 | - | Growth Inhibition Assay | - | IC50=0.06143 μM | SANGER |
D-247MG | - | Growth Inhibition Assay | - | IC50=32.9773 μM | SANGER |
D-283MED | - | Growth Inhibition Assay | - | IC50=10.9176 μM | SANGER |
D-336MG | - | Growth Inhibition Assay | - | IC50=0.50304 μM | SANGER |
Daudi | - | Growth Inhibition Assay | - | IC50=27.0773 μM | SANGER |
DEL | - | Growth Inhibition Assay | - | IC50=42.0522 μM | SANGER |
DOHH-2 | - | Growth Inhibition Assay | - | IC50=1.71782 μM | SANGER |
EB-3 | - | Growth Inhibition Assay | - | IC50=36.9518 μM | SANGER |
ECC4 | - | Growth Inhibition Assay | - | IC50=17.0277 μM | SANGER |
EC-GI-10 | - | Growth Inhibition Assay | - | IC50=24.5989 μM | SANGER |
EKVX | - | Growth Inhibition Assay | - | IC50=26.0203 μM | SANGER |
EM-2 | - | Growth Inhibition Assay | - | IC50=0.265 μM | SANGER |
EoL-1-cell | - | Growth Inhibition Assay | - | IC50=9.30192 μM | SANGER |
ES1 | - | Growth Inhibition Assay | - | IC50=28.7773 μM | SANGER |
ES3 | - | Growth Inhibition Assay | - | IC50=17.4655 μM | SANGER |
ES4 | - | Growth Inhibition Assay | - | IC50=6.53074 μM | SANGER |
ES6 | - | Growth Inhibition Assay | - | IC50=27.9123 μM | SANGER |
ETK-1 | - | Growth Inhibition Assay | - | IC50=3.20767 μM | SANGER |
EVSA-T | - | Growth Inhibition Assay | - | IC50=10.6568 μM | SANGER |
EW-16 | - | Growth Inhibition Assay | - | IC50=1.55083 μM | SANGER |
EW-24 | - | Growth Inhibition Assay | - | IC50=0.62693 μM | SANGER |
GB-1 | - | Growth Inhibition Assay | - | IC50=1.79833 μM | SANGER |
GCIY | - | Growth Inhibition Assay | - | IC50=2.87005 μM | SANGER |
GDM-1 | - | Growth Inhibition Assay | - | IC50=8.97292 μM | SANGER |
GI-1 | - | Growth Inhibition Assay | - | IC50=2.16084 μM | SANGER |
GOTO | - | Growth Inhibition Assay | - | IC50=37.3224 μM | SANGER |
HAL-01 | - | Growth Inhibition Assay | - | IC50=44.5034 μM | SANGER |
HCC1599 | - | Growth Inhibition Assay | - | IC50=36.7053 μM | SANGER |
HCE-4 | - | Growth Inhibition Assay | - | IC50=46.5968 μM | SANGER |
HCE-T | - | Growth Inhibition Assay | - | IC50=47.6828 μM | SANGER |
HH | - | Growth Inhibition Assay | - | IC50=20.0099 μM | SANGER |
HOP-62 | - | Growth Inhibition Assay | - | IC50=1.50246 μM | SANGER |
HT-144 | - | Growth Inhibition Assay | - | IC50=42.1676 μM | SANGER |
HUTU-80 | - | Growth Inhibition Assay | - | IC50=6.98466 μM | SANGER |
IST-MEL1 | - | Growth Inhibition Assay | - | IC50=23.8658 μM | SANGER |
IST-SL2 | - | Growth Inhibition Assay | - | IC50=2.72379 μM | SANGER |
JiyoyeP-2003 | - | Growth Inhibition Assay | - | IC50=46.0119 μM | SANGER |
K5 | - | Growth Inhibition Assay | - | IC50=28.1287 μM | SANGER |
K-562 | - | Growth Inhibition Assay | - | IC50=0.44967 μM | SANGER |
KALS-1 | - | Growth Inhibition Assay | - | IC50=1.98722 μM | SANGER |
KARPAS-422 | - | Growth Inhibition Assay | - | IC50=47.0895 μM | SANGER |
KARPAS-45 | - | Growth Inhibition Assay | - | IC50=44.3925 μM | SANGER |
KGN | - | Growth Inhibition Assay | - | IC50=1.27687 μM | SANGER |
KINGS-1 | - | Growth Inhibition Assay | - | IC50=4.82373 μM | SANGER |
KLE | - | Growth Inhibition Assay | - | IC50=6.78377 μM | SANGER |
KM12 | - | Growth Inhibition Assay | - | IC50=4.32416 μM | SANGER |
KNS-42 | - | Growth Inhibition Assay | - | IC50=3.65 μM | SANGER |
KP-N-YS | - | Growth Inhibition Assay | - | IC50=23.9255 μM | SANGER |
KS-1 | - | Growth Inhibition Assay | - | IC50=1.19779 μM | SANGER |
KU812 | - | Growth Inhibition Assay | - | IC50=3.05299 μM | SANGER |
KURAMOCHI | - | Growth Inhibition Assay | - | IC50=4.65256 μM | SANGER |
L-540 | - | Growth Inhibition Assay | - | IC50=18.8109 μM | SANGER |
LAMA-84 | - | Growth Inhibition Assay | - | IC50=0.1599 μM | SANGER |
LB1047-RCC | - | Growth Inhibition Assay | - | IC50=1.55453 μM | SANGER |
LB2518-MEL | - | Growth Inhibition Assay | - | IC50=33.7666 μM | SANGER |
LB647-SCLC | - | Growth Inhibition Assay | - | IC50=17.4949 μM | SANGER |
LB771-HNC | - | Growth Inhibition Assay | - | IC50=14.7898 μM | SANGER |
LB996-RCC | - | Growth Inhibition Assay | - | IC50=0.44196 μM | SANGER |
LC-1F | - | Growth Inhibition Assay | - | IC50=29.7346 μM | SANGER |
LC-2-ad | - | Growth Inhibition Assay | - | IC50=3.557 μM | SANGER |
LC4-1 | - | Growth Inhibition Assay | - | IC50=9.00911 μM | SANGER |
LOXIMVI | - | Growth Inhibition Assay | - | IC50=33.7928 μM | SANGER |
LS-123 | - | Growth Inhibition Assay | - | IC50=5.49684 μM | SANGER |
LXF-289 | - | Growth Inhibition Assay | - | IC50=3.12109 μM | SANGER |
MEG-01 | - | Growth Inhibition Assay | - | IC50=0.23688 μM | SANGER |
MFH-ino | - | Growth Inhibition Assay | - | IC50=1.7787 μM | SANGER |
MLMA | - | Growth Inhibition Assay | - | IC50=9.15006 μM | SANGER |
MONO-MAC-6 | - | Growth Inhibition Assay | - | IC50=33.5048 μM | SANGER |
MPP-89 | - | Growth Inhibition Assay | - | IC50=23.2289 μM | SANGER |
MSTO-211H | - | Growth Inhibition Assay | - | IC50=2.35723 μM | SANGER |
MV-4-11 | - | Growth Inhibition Assay | - | IC50=4.81344 μM | SANGER |
MZ1-PC | - | Growth Inhibition Assay | - | IC50=2.29356 μM | SANGER |
NB1 | - | Growth Inhibition Assay | - | IC50=11.0242 μM | SANGER |
NB10 | - | Growth Inhibition Assay | - | IC50=18.5256 μM | SANGER |
NB17 | - | Growth Inhibition Assay | - | IC50=45.6643 μM | SANGER |
NB5 | - | Growth Inhibition Assay | - | IC50=4.41864 μM | SANGER |
NB6 | - | Growth Inhibition Assay | - | IC50=27.488 μM | SANGER |
NB69 | - | Growth Inhibition Assay | - | IC50=1.37497 μM | SANGER |
NB7 | - | Growth Inhibition Assay | - | IC50=11.3297 μM | SANGER |
NCCIT | - | Growth Inhibition Assay | - | IC50=0.73218 μM | SANGER |
NCI-H1355 | - | Growth Inhibition Assay | - | IC50=11.1806 μM | SANGER |
NCI-H1436 | - | Growth Inhibition Assay | - | IC50=0.79049 μM | SANGER |
NCI-H1648 | - | Growth Inhibition Assay | - | IC50=0.28116 μM | SANGER |
NCI-H209 | - | Growth Inhibition Assay | - | IC50=35.144 μM | SANGER |
NCI-H2126 | - | Growth Inhibition Assay | - | IC50=19.51 μM | SANGER |
NCI-H720 | - | Growth Inhibition Assay | - | IC50=46.7682 μM | SANGER |
NCI-H747 | - | Growth Inhibition Assay | - | IC50=2.25714 μM | SANGER |
NMC-G1 | - | Growth Inhibition Assay | - | IC50=6.01811 μM | SANGER |
NOS-1 | - | Growth Inhibition Assay | - | IC50=0.60529 μM | SANGER |
OS-RC-2 | - | Growth Inhibition Assay | - | IC50=1.88574 μM | SANGER |
OVCAR-4 | - | Growth Inhibition Assay | - | IC50=3.73433 μM | SANGER |
PF-382 | - | Growth Inhibition Assay | - | IC50=3.83698 μM | SANGER |
PSN1 | - | Growth Inhibition Assay | - | IC50=47.7813 μM | SANGER |
QIMR-WIL | - | Growth Inhibition Assay | - | IC50=8.42808 μM | SANGER |
Ramos-2G6-4C10 | - | Growth Inhibition Assay | - | IC50=47.1622 μM | SANGER |
RCC10RGB | - | Growth Inhibition Assay | - | IC50=44.7392 μM | SANGER |
RL95-2 | - | Growth Inhibition Assay | - | IC50=1.66902 μM | SANGER |
RPMI-6666 | - | Growth Inhibition Assay | - | IC50=12.9567 μM | SANGER |
RPMI-8402 | - | Growth Inhibition Assay | - | IC50=11.178 μM | SANGER |
RXF393 | - | Growth Inhibition Assay | - | IC50=1.2436 μM | SANGER |
SCLC-21H | - | Growth Inhibition Assay | - | IC50=30.7317 μM | SANGER |
SF126 | - | Growth Inhibition Assay | - | IC50=3.31174 μM | SANGER |
SF268 | - | Growth Inhibition Assay | - | IC50=5.61262 μM | SANGER |
SH-4 | - | Growth Inhibition Assay | - | IC50=4.25259 μM | SANGER |
SKM-1 | - | Growth Inhibition Assay | - | IC50=14.4499 μM | SANGER |
SK-N-DZ | - | Growth Inhibition Assay | - | IC50=1.84688 μM | SANGER |
SK-PN-DW | - | Growth Inhibition Assay | - | IC50=32.5598 μM | SANGER |
SK-UT-1 | - | Growth Inhibition Assay | - | IC50=45.9464 μM | SANGER |
SNB75 | - | Growth Inhibition Assay | - | IC50=2.68594 μM | SANGER |
SNU-C2B | - | Growth Inhibition Assay | - | IC50=7.82737 μM | SANGER |
SR | - | Growth Inhibition Assay | - | IC50=6.58807 μM | SANGER |
ST486 | - | Growth Inhibition Assay | - | IC50=1.45852 μM | SANGER |
SW684 | - | Growth Inhibition Assay | - | IC50=41.8495 μM | SANGER |
SW872 | - | Growth Inhibition Assay | - | IC50=2.18507 μM | SANGER |
SW954 | - | Growth Inhibition Assay | - | IC50=2.57408 μM | SANGER |
SW962 | - | Growth Inhibition Assay | - | IC50=2.17178 μM | SANGER |
SW982 | - | Growth Inhibition Assay | - | IC50=1.92093 μM | SANGER |
TE-1 | - | Growth Inhibition Assay | - | IC50=1.44105 μM | SANGER |
TE-10 | - | Growth Inhibition Assay | - | IC50=1.66252 μM | SANGER |
TE-11 | - | Growth Inhibition Assay | - | IC50=1.43418 μM | SANGER |
TE-12 | - | Growth Inhibition Assay | - | IC50=0.3268 μM | SANGER |
TE-15 | - | Growth Inhibition Assay | - | IC50=0.27412 μM | SANGER |
TE-5 | - | Growth Inhibition Assay | - | IC50=33.0362 μM | SANGER |
TE-6 | - | Growth Inhibition Assay | - | IC50=14.7591 μM | SANGER |
TE-8 | - | Growth Inhibition Assay | - | IC50=0.87275 μM | SANGER |
TE-9 | - | Growth Inhibition Assay | - | IC50=43.4596 μM | SANGER |
TGBC1TKB | - | Growth Inhibition Assay | - | IC50=26.434 μM | SANGER |
TGBC24TKB | - | Growth Inhibition Assay | - | IC50=2.05958 μM | SANGER |
TK10 | - | Growth Inhibition Assay | - | IC50=0.90669 μM | SANGER |
VA-ES-BJ | - | Growth Inhibition Assay | - | IC50=13.9234 μM | SANGER |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01144481 | - | - | Completed | - | Canada, Ontario ... more >> University Health Network Toronto, Ontario, Canada, M5G 2C4 Collapse << |
NCT00265876 | Pancreatic Cancer | Phase 1 Phase 2 | Completed | - | Canada, British Columbia ... more >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Algoma District Cancer Program Sault Ste. Marie, Ontario, Canada, P6B 0A8 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT01000896 | Cancer Non Sm... more >>all Cell Lung Cancer Epithelial Ovarian Cancer Collapse << | Phase 1 | Withdrawn(AstraZeneca has disc... more >>ontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..) Collapse << | March 2011 | Japan ... more >> Research Site Matsuyama, Ehime, Japan Research Site Fukuoka, Japan Collapse << |
NCT00853983 | Healthy | Phase 1 | Completed | - | United Kingdom ... more >> Research Site Alderley Park, Cheshire, United Kingdom Collapse << |
NCT00496028 | Neoplasms | Phase 1 | Completed | - | France ... more >> Research Site Paris, France Research Site Pierre Benite Cedex, France Netherlands Research Site Amsterdam, Netherlands Research Site Groningen, Netherlands Norway Research Site Oslo, Norway United Kingdom Research Site Glasgow, United Kingdom Research Site Sutton, United Kingdom Collapse << |
NCT00475956 | Neoplasms | Phase 1 | Completed | - | Germany ... more >> Research Site Freiburg, Baden-Wurttemberg, Germany Research Site Essen, Ruhr, Germany Research Site Herne, Ruhr, Germany Collapse << |
NCT00735917 | Adenocarcinoma of the Pancreas... more >> Recurrent Pancreatic Cancer Stage IV Pancreatic Cancer Collapse << | Phase 2 | Completed | - | United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Colorado University of Colorado at Denver Aurora, Colorado, United States, 80045 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Australia, Western Australia Sir Charles Gairdner Hospital Nedlands, Western Australia, Australia, 6009 Singapore National University Hospital Singapore, Singapore, 119074 Collapse << |
NCT00610714 | - | - | Completed | - | - |
NCT01216176 | Breast Cancer | Phase 1 Phase 2 | Completed | - | United States, California ... more >> Stanford University Palo Alto, California, United States, 94304 United States, Florida University of Miami Miami, Florida, United States, 33136 Collapse << |
NCT00610714 | Ovarian Neoplasms ... more >> Ovarian Cancer Collapse << | Phase 2 | Completed | - | - |
NCT00771979 | Healthy | Phase 1 | Completed | - | United Kingdom ... more >> Research Site Alderley Park, United Kingdom Collapse << |
NCT00558272 | Breast Cancer ... more >> Prostate Cancer Bone Neoplasms Collapse << | Phase 2 | Completed | - | - |
NCT00735917 | - | - | Completed | - | - |
NCT00558272 | - | - | Completed | - | - |
NCT01196741 | - | - | Completed | - | - |
NCT00704366 | Solid Tumor | Phase 1 | Completed | - | Japan ... more >> Research Site Takatsuk, Osaka, Japan Research Site Sunto-gun, Shizuoka, Japan Collapse << |
NCT00752206 | Osteosarcoma | Phase 2 | Completed | - | United States, Alabama ... more >> University of Alabama Birmingham, Alabama, United States, 35233 United States, California Children's Hospital Los Angeles Los Angeles, California, United States, 90027 USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90089 UCLA/Mattel's Children's Hospital Los Angeles, California, United States, 90095 Stanford University Palo Alto, California, United States, 94304 UCSF San Francisco, California, United States, 94143 Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, Florida University of Florida Gainesville, Florida, United States, 32610 University of Miami Miami, Florida, United States United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Iowa University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 United States, Maryland Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21231 National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48106 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Washington Seattle Cancer Care Alliance/University of Washington Medical Center Seattle, Washington, United States, 98109 Collapse << |
NCT01196741 | Ovarian Cancer ... more >> Fallopian Tube Cancer Primary Peritoneal Cancer Collapse << | Phase 2 Phase 3 | Completed | - | United Kingdom ... more >> Addenbrooke's Hospital Cambridge, Cambridgeshire, United Kingdom, BC2 0QQ St Bartholomew's Hospital London, Greater London, United Kingdom, EC1A 7BE University College London Hospital London, Greater London, United Kingdom, NW1 2PG Guy's Hospital London, Greater London, United Kingdom, SE1 9RT The Royal Mardsen Hospital London, Greater London, United Kingdom, SW3 6JJ The Christie NHS Foundation Trust Manchester, Greater Manchester, United Kingdom, M20 4BX Mount Vernon Hospital Rickmansworth, Middlesex, United Kingdom, HA6 2RN The Churchill Hospital Oxford, Oxfordshire, United Kingdom, OX3 7LJ Queen's Hospital Burton upon Trent, Staffordshire, United Kingdom, DE13 0RB Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT St James's University Hospital Leeds, Yorkshire, United Kingdom, LS9 7TF Beatson West of Scotland Cancer Centre Glasgow, United Kingdom, G12 0YN Collapse << |
NCT02167256 | Alzheimer's Disease | Phase 2 | Completed | - | - |
NCT00659360 | Adult Fibrosarcoma ... more >> Adult Leiomyosarcoma Adult Liposarcoma Adult Malignant Fibrous Histiocytoma Adult Rhabdomyosarcoma Dermatofibrosarcoma Protuberans Endometrial Stromal Sarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Uterine Sarcoma Stage III Adult Soft Tissue Sarcoma Stage III Uterine Sarcoma Stage IV Adult Soft Tissue Sarcoma Stage IV Uterine Sarcoma Uterine Carcinosarcoma Uterine Leiomyosarcoma Collapse << | Phase 2 | Completed | - | United States, Pennsylvania ... more >> Fox Chase Cancer Center Rockledge, Pennsylvania, United States, 19046 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Montreal General Hospital Montreal, Quebec, Canada, H3G 1A4 Collapse << |
NCT00397878 | - | - | Terminated | - | - |
NCT02262026 | Alcoholism | Phase 1 | Recruiting | April 28, 2019 | United States, Connecticut ... more >> Hartford Hospital Recruiting Hartford, Connecticut, United States, 06102 Contact: Godfrey Pearlson, MD 203-737-3416 godfrey.pearlson@hhchealth.org Collapse << |
NCT00513071 | Hormone-resistant Prostate Can... more >>cer Recurrent Prostate Cancer Collapse << | Phase 2 | Completed | - | United States, California ... more >> City of Hope Duarte, California, United States, 91010 Collapse << |
NCT00513071 | - | - | Completed | - | - |
NCT00397878 | Adenocarcinoma of the Colon ... more >> Adenocarcinoma of the Rectum Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Collapse << | Phase 2 | Terminated | - | United States, Texas ... more >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT00513435 | - | - | Completed | - | - |
NCT00659360 | - | - | Completed | - | - |
NCT00718809 | Invasive Thymoma and Thymic Ca... more >>rcinoma Recurrent Thymoma and Thymic Carcinoma Stage III Thymoma Stage IVA Thymoma Stage IVB Thymoma Collapse << | Phase 2 | Terminated | - | United States, California ... more >> Stanford University Hospitals and Clinics Stanford, California, United States, 94305 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 Collapse << |
NCT00513435 | Metastatic Squamous Neck Cance... more >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Stage III Squamous Cell Carcinoma of the Hypopharynx Stage III Squamous Cell Carcinoma of the Larynx Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Stage III Squamous Cell Carcinoma of the Nasopharynx Stage III Squamous Cell Carcinoma of the Oropharynx Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage III Verrucous Carcinoma of the Larynx Stage III Verrucous Carcinoma of the Oral Cavity Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IVA Squamous Cell Carcinoma of the Larynx Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVA Verrucous Carcinoma of the Larynx Stage IVA Verrucous Carcinoma of the Oral Cavity Stage IVB Squamous Cell Carcinoma of the Larynx Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Larynx Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Squamous Cell Carcinoma of the Larynx Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Collapse << | Phase 2 | Completed | - | United States, New York ... more >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT00559507 | - | - | Completed | - | - |
NCT00718809 | - | - | Terminated | - | - |
NCT01267266 | - | - | Terminated(Per protocol, study... more >> was terminated due to low rate of randomized patients.) Collapse << | - | - |
NCT00559507 | Estrogen Receptor-negative Bre... more >>ast Cancer Male Breast Cancer Progesterone Receptor-negative Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Collapse << | Phase 2 | Completed | - | United States, New York ... more >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT00528645 | Extensive Stage Small Cell Lun... more >>g Cancer Lung Metastases Malignant Pleural Effusion Recurrent Small Cell Lung Cancer Collapse << | Phase 2 | Completed | - | United States, Minnesota ... more >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 Collapse << |
NCT00638937 | Recurrent Non-small Cell Lung ... more >>Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Collapse << | Phase 2 | Completed | - | Canada, Ontario ... more >> Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus Ottawa, Ontario, Canada, K1Y 4E9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec McGill University Department of Oncology Montreal, Quebec, Canada, H2W 1S6 Collapse << |
NCT00528645 | - | - | Completed | - | - |
NCT00607594 | - | - | Completed | - | - |
NCT00607594 | Adenocarcinoma of the Gastroes... more >>ophageal Junction Adenocarcinoma of the Stomach Recurrent Gastric Cancer Stage III Gastric Cancer Stage III Esophageal Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer Collapse << | Phase 2 | Completed | - | United States, Georgia ... more >> Hamilton Medical Center Dalton, Georgia, United States, 30720 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec McGill University Department of Oncology Montreal, Quebec, Canada, H2W 1S6 Collapse << |
NCT02955186 | Alcohol Drinking | Phase 2 | Recruiting | June 2021 | United States, Connecticut ... more >> CMHC, Substance Abuse Center Recruiting New Haven, Connecticut, United States, 06519 Contact: Dana A Cavallo, Ph.D. 203-974-7607 dana.cavallo@yale.edu Principal Investigator: Suchitra Krishnan-Sarin, Ph.D. Collapse << |
NCT00638937 | - | - | Completed | - | - |
NCT02085603 | Cancer | Phase 2 | Completed | - | United Kingdom ... more >> Sheffield Teaching Hospitals NHS Trust Sheffield, South Yorkshire, United Kingdom, S10 1SN Collapse << |
NCT01267266 | Hormone-resistant Prostate Can... more >>cer Recurrent Prostate Cancer Stage IV Prostate Cancer Collapse << | Phase 2 | Terminated(Per protocol, study... more >> was terminated due to low rate of randomized patients.) Collapse << | - | United States, Illinois ... more >> University of Chicago Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States, 60201 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 Loyola University Medical Center Maywood, Illinois, United States, 60153 Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 60702 Southern Illinois University Springfield, Illinois, United States, 62702 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne, Indiana, United States, 46845 United States, Maryland University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Missouri Saint John's Mercy Medical Center Saint Louis, Missouri, United States, 63141 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Women's Health Center Madison, Wisconsin, United States, 53715 Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse << |
NCT00669019 | - | - | Completed | - | - |
NCT02732587 | Alcohol Drinking | Phase 1 | Completed | - | United States, Connecticut ... more >> CMHC, Substance Abuse Center New Haven, Connecticut, United States, 06519 Collapse << |
NCT03661125 | Parkinson Disease Psychosis | Early Phase 1 | Not yet recruiting | September 1, 2021 | United Kingdom ... more >> Mitul Mehta Not yet recruiting London, Camberwell, United Kingdom, SE5 8AF Contact: Mitul Mehta +44 (0)2032283053 mitul.mehta@kcl.ac.uk Contact: Miriam Vignando 07492634351 miriam.vignando@kcl.ac.uk Collapse << |
NCT00669019 | Recurrent Melanoma ... more >> Stage IIA Melanoma Stage IIB Melanoma Stage IIC Melanoma Stage IV Melanoma Collapse << | Phase 2 | Completed | - | United States, Illinois ... more >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 Collapse << |
NCT01864655 | Alzheimer's Disease | Phase 1 | Completed | - | United States, Connecticut ... more >> Yale Alzheimer's Disease Research Unit New Haven, Connecticut, United States, 06510 Collapse << |
NCT02737202 | Pulmonary Lymphangioleiomyomat... more >>osis Collapse << | Phase 2 | Recruiting | July 30, 2020 | United States, California ... more >> Stanford University Recruiting Stanford, California, United States, 94305 Contact: Susan Jacobs, RN MS 650-725-8083 ssjpulm@stanford.edu Principal Investigator: Stephen Ruoss, MD United States, Illinois Loyola Medical Center Recruiting Chicago, Illinois, United States, 90153 Contact: Elizabeth Kirwan, RN 708-216-2057 ekirwan@luc.edu Principal Investigator: Daniel Dilling, MD United States, Maryland Laboratory of Translational Research NHLBI Recruiting Bethesda, Maryland, United States, 20814 Contact: Mary Haughey, RN 301-496-3632 mhaughey@nhlbi.nih.gov Principal Investigator: Joel Moss, MD United States, Ohio University of Cincinnati Recruiting Cincinnati, Ohio, United States, 45267 Contact: Tammy Roads 513-558-2148 roadst@ucmail.uc.edu Principal Investigator: Frank X McCormack, MD United States, Texas Baylor College of Medicine - Ben Taub General Hospital Recruiting Houston, Texas, United States, 77030 Contact: Caryn O Pope 713-873-2471 cpope@bcm.edu Principal Investigator: Nicola A Hanania, MD Collapse << |
NCT02116712 | Pulmonary Lymphangioleiomyomat... more >>osis Collapse << | Phase 1 | Completed | - | United States, Ohio ... more >> University of Cincinnati Cincinnati, Ohio, United States, 45267 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 University of Texas Health Science Center-Houston Houston, Texas, United States, 77030 Collapse << |
靶点 | Description | IC50 |
---|---|---|
Src | IC50:2.7nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网